Ep 14 Adult Stem Cells for Advanced Dry Macular Degeneration

A look at emerging clinical research showing how adult stem cell transplantation may offer early visual improvements and a new therapeutic pathway for patients with advanced dry AMD and geographic atrophy.

To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

FULL TRANSCRIPT

Dry age-related macular degeneration, also known as dry AMD, is one of the most common causes of irreversible vision loss in adults over 65. Its advanced form, called geographic atrophy, leads to the progressive breakdown of retinal cells and has few effective treatment options.

Unlike wet AMD, which can be managed with injections, advanced dry AMD lacks therapies that can restore lost vision. This has created an urgent need for new solutions - and that’s where adult stem cells may come in.

Emerging research suggests that adult stem cell transplantation could offer a new path forward. Rather than simply slowing disease progression, stem cell therapies are being studied for their ability to support visual function and preserve retinal structure.

Let’s take a closer look at why adult stem cells are drawing so much interest in this area.

Adult stem cells, including mesenchymal stem cells and retinal progenitor cells, are known for their anti-inflammatory and immune-modulating properties. They can be ethically sourced from bone marrow or umbilical tissue and do not carry the tumor risks associated with embryonic or pluripotent stem cells.

In animal models, these cells have been shown to preserve photoreceptors, reduce inflammation in the eye, and even improve visual responses. This laid the groundwork for early human trials.

Several small, early-phase clinical studies have explored subretinal injections of these cells in patients with geographic atrophy. So far, results are cautiously optimistic. Most trials have reported no serious safety issues. And in some cases, participants experienced modest improvements in visual acuity or contrast sensitivity over the course of 6 to 12 months.

Imaging studies have also shown stabilization in areas of retinal atrophy, suggesting the potential for real biological impact.

How do these cells work?

One mechanism is paracrine signaling - where the transplanted cells don’t necessarily become new retinal cells, but instead release beneficial signals. These may enhance the survival of photoreceptors, protect the retinal pigment epithelium, and regulate inflammation. In some cases, retinal progenitor cells may even integrate into retinal layers and contribute to structural repair.

The preferred method of delivery is subretinal injection, placing the cells directly into the space between the retina and its supporting layer. This ensures close contact with damaged tissue while minimizing systemic exposure and the risk of unwanted cell migration.

Innovations like image-guided microinjections have improved safety and precision in these procedures, reducing the risk of complications.

Of course, stem cell therapy isn’t without its challenges.

Ensuring consistent quality and viability of cell batches - especially for off-the-shelf or donor-based products - is critical. Long-term durability of the benefits is still being studied. And researchers are working to identify reliable biomarkers to track whether the therapy is truly working.

Most trials now include rigorous visual testing, OCT imaging, and biomarker analysis over one to two years. Regulatory agencies, including the FDA, require this kind of detailed validation before allowing stem cell therapies to move into broader use.

So what comes next?

Larger phase 2 trials are now underway, aiming to confirm the early signals seen in smaller studies. Some research is exploring combination approaches - pairing stem cells with gene therapies or drugs that target other parts of the disease pathway. Others are looking at personalized stem cell lines for use in high-risk individuals.

And with the help of AI-assisted retinal imaging, physicians may soon be able to detect changes earlier and tailor treatment more precisely to each patient.

While stem cells for dry AMD are still investigational, their potential is significant. For patients with few existing options, they represent a new frontier in vision care - one focused not just on slowing loss, but on supporting real regeneration.

Here are a few frequently asked questions.

Are stem cells currently FDA-approved for dry AMD?
No. These therapies are still being studied and are not yet approved for routine clinical use.

How are the cells delivered?
Most studies use subretinal injection, placing the cells directly behind the retina near areas of damage.

Can stem cells actually improve vision?
Some trials have shown improvements in vision and retinal structure, but larger studies are needed to confirm these effects.

Are there any risks?
Like any eye surgery, there are risks, including infection, inflammation, or retinal detachment. Most events so far have been mild.

What’s next in research?
Researchers are studying which cell types, doses, and delivery methods work best - and how long benefits might last.

Thanks for listening.

Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.